Highlights and Quick Summary
- Average Receivables for the quarter ending June 30, 2023 was $233 Million (a 37.73% increase compared to previous quarter)
- Year-over-year quarterly Average Receivables increased by 4.31%
- Annual Average Receivables for 2022 was $217 Million (a -14.34% decrease from previous year)
- Annual Average Receivables for 2021 was $253 Million (a 0.8% increase from previous year)
- Annual Average Receivables for 2020 was $251 Million (a -7.42% decrease from previous year)
Visit stockrow.com/EBS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Average Receivables of Emergent Biosolutions Inc.
Most recent Average Receivablesof EBS including historical data for past 10 years.Interactive Chart of Average Receivables of Emergent Biosolutions Inc.
Emergent Biosolutions Inc. Average Receivables for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $232.55 | $168.85 | – | – | – |
| 2022 | $216.55 | $222.95 | $218.45 | $183.1 | $216.55 |
| 2021 | $252.8 | $225.35 | $260.25 | $178.55 | $252.8 |
| 2020 | $250.8 | $238.65 | $238.35 | $147.1 | $250.8 |
| 2019 | $270.9 | $179.08 | $203.79 | $125.32 | $270.9 |
| 2018 | $208.6 | $103.16 | $149.06 | $131.99 | $208.6 |
| 2017 | $147.29 | $105.41 | $92.28 | $104.09 | $147.29 |
| 2016 | $134.48 | $70.97 | $94.4 | $77.21 | $134.48 |
| 2015 | $90.34 | $56.42 | $103.9 | $80.91 | $90.34 |
| 2014 | $63.21 | $41.53 | $77.91 | $77.23 | $63.21 |
| 2013 | $81.14 | $28.69 | $59.05 | $68.59 | $81.14 |
| 2012 | $89.85 | – | – | – | $89.85 |
Business Profile of Emergent Biosolutions Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic